Pharmaceutical companies Novo Nordisk (NYSE: NVO) and (NYSE: ABBV) seem to be headed in separate directions.

Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and obesity therapy Wegovy, is predicting sales to grow between 24% to 30% and operating profit to rise 28% to 34% this year.

AbbVie, on the other hand, thanks to the loss of patent protection for immunology blockbuster Humira, has forecasted 2023 adjusted earnings per share (EPS) to drop by 20% to 23%, from 2022 levels.  Both stocks rewarded investors over the past decade, but for the long term, which is a better buy right now? Let's find out.

Continue reading

Source Fool.com